

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT RECOGNITION OF A SUBSIDIARY AS A SPECIALIZED AND NEW SMALL AND MEDIUM-SIZED ENTERPRISE OF SHANGHAI

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, the Shanghai Municipal Commission of Economy and Informatization* (上海市經濟和信息化委員會) has recently published the list of Specialized and New Small and Medium-Sized Enterprises (“**Specialized and New SMEs**”) of Shanghai Municipal in 2024* (2024年上海市專精特新中小企業) pursuant to the Implementation Rules for Gradient Cultivation and Management of High-quality Small and Medium-sized Enterprises in Shanghai* (《上海市優質中小企業梯度培育管理實施細則》), among which Shanghai Longyao Biotech Company Limited* (上海隆耀生物科技有限公司) (“**Shanghai Longyao**”), an indirect non-wholly owned subsidiary of the Company, has been recognized as a Specialized and New SME of Shanghai in 2024.

Specialized and New SMEs refers to small and medium-sized enterprises with the characteristics of “specialization, refinement, differentiation, innovation” and exceptional performance in terms of technology, market, quality and efficiency. It is an important part of the gradient cultivation system for quality enterprises in Shanghai.

The categorization of Shanghai Longyao as a Specialized and New SME is a significant recognition of the Company's commitment to the long-term development and continuous innovation in the field of the chimeric antigen receptor T (“**CAR-T**”) therapy. Such categorization positions Shanghai Longyao as a key entity that will receive more resources and policy support from the Shanghai Municipal Commission of Economy and Informatization. It would also enhance Shanghai Longyao's research and development capability, elevate its brand awareness, and strengthen its market competitiveness in the area of CAR-T therapy.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 9 May 2024

As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song; one non-executive Director, namely, Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.

** The English transliteration of the Chinese name is for identification purposes only. If there is any inconsistency, the Chinese name shall prevail.*